Earnings call transcripts

Management framed 2023 around maintaining earnings while repositioning the balance sheet and defining growth beyond the $10 billion Durbin limit.

Management framed 2022 as strong share-gain execution but reset costs and profitability timing after weaker European demand and channel caution.

Management framed performance as broad-based, with GLP-1 demand driving growth while supply constraints and declining insulin sales shaped the outlook. 40% of U.S.

Management framed the reset as temporary China demand deferral and currency pressure, while shifting resources toward EVO and signaling stronger U.S. momentum.

Management framed the quarter as share gains and execution against a softer European EV market, with near-term caution but confidence in long-term growth.

Management framed the quarter as a deliberate trade-off: protect credit quality now while preserving capacity to resume growth when conditions improve.

Management framed the raised outlook around accelerating GLP-1 demand, while emphasizing capacity expansion and continued investment to address supply constraints.

Management framed the quarter as on plan, with strong liquidity and progress toward A-sample development, while commercialization remains several milestones away.

Management framed growth as broad-based EVO adoption overcoming currency and COVID disruptions, while stressing U.S. launch investment and refusing to quantify U.S. growth.

Management framed the quarter as resilient but stressed that 2022 lockdowns pose a deeper, less predictable operating shock than 2020.

Management framed the quarter as demand-led growth strong enough to raise the outlook, while stressing that supply capacity—not demand—would limit near-term GLP-1 sales.

Management framed the quarter around strong global ICL demand and a newly opened U.S. growth opportunity, while highlighting China lockdowns and launch spending timing. 600 U.S.